Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2021
October 2021, Vol 12, No 5
October 2021, Vol 12, No 5
Balstilimab Shows Promise in the Treatment of Advanced Cervical Cancer
By
Wayne Kuznar
Cervical Cancer
October 2021, Vol 12, No 5
According to results from a recent study, balstilimab, an investigational PD-1 inhibitor, demonstrated meaningful and durable clinical activity in patients with recurrent or metastatic cervical cancer. These findings were presented by Cailin E. Joyce, MD, Director, Applied Technology, Agenus, Boston, MA, during the American Society of Clinical Oncology 2021 virtual annual meeting
Read More
Olaparib, a PARP Inhibitor, Prolongs Disease-Free Survival in Patients with Early-Stage Breast Cancer and BRCA Mutation
By
Walter Alexander
Breast Cancer
October 2021, Vol 12, No 5
The use of the PARP inhibitor olaparib (Lynparza) for 1 year after receiving standard chemotherapy in the neoadjuvant or the adjuvant setting significantly improved invasive disease-free survival in patients with high-risk, early-stage,
HER2
-negative breast cancer and BRCA1 or BRCA2 mutations, according to results presented at the American Society of Clinical Oncology 2021 virtual meeting.
Read More
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2 Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
By
Chase Doyle
Breast Cancer
October 2021, Vol 12, No 5
The addition of the tyrosine kinase inhibitor tucatinib (Tukysa) to trastuzumab (Herceptin) and capecitabine continued to improve overall survival (OS) and progression-free survival (PFS) in patients with HER2 positive metastatic breast cancer, according to updated results from the pivotal HER2CLIMB trial. The findings were presented at the American Society of Clinical Oncology 2021 virtual annual meeting by lead investigator Giuseppe Curigliano, MD, PhD, Associate Professor, Medical Oncology, University of Milano, Italy, and Director, New Drugs and Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, San Giovanni Rotondo, Italy.
Read More
Breast Reconstruction Disparities Improve Significantly with Medicaid Expansion
By
Walter Alexander
Value-Based Care
October 2021, Vol 12, No 5
Medicaid expansion under the Affordable Care Act was associated with significant increases in breast reconstruction surgery among non-Hispanic black women and women with lower income and education levels, according to results of a study presented during the American Society of Breast Surgeons 22nd Annual Meeting. At times, these increases achieved parity with non-Hispanic white women.
Read More
Lisaftoclax Demonstrates Preliminary Efficacy and Tolerability in Relapsed or Refractory CLL/SLL
By
Phoebe Starr
Hematologic Malignancies
,
Leukemia
October 2021, Vol 12, No 5
The novel BCL-2 inhibitor, lisaftoclax (APG-2575), elicited encouraging responses and acceptable tolerability in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other hematologic malignancies, according to results of a phase 1 study presented at the American Society of Clinical Oncology 2021 virtual annual meeting.
Read More
Role of Radiology in Intrahepatic Cholangiocarcinoma Addressed at the 2021 Interventional Oncology Meetings
Cholangiocarcinoma
October 2021, Vol 12, No 5
Key topics related to intrahepatic cholangiocarcinoma (CCA) were presented at the 2021 Society of Interventional Oncology (SIO) and the Society of Interventional Radiology (SIR) meetings and were discussed during the CCA Summit. Bruno C. Odisio, MD, FSIR, Interventional Radiologist and Co-Director of Research, Department of Interventional Radiology, M.D. Anderson Cancer Center, Houston, TX, reviewed the significance of these findings.
Read More
FDA Approves Lenvima plus Keytruda Combo for Advanced Renal-Cell Carcinoma
FDA Approvals, News & Updates
October 2021, Vol 12, No 5
On August 10, 2021, the FDA approved the combination of lenvatinib (Lenvima; Eisai) plus pembrolizumab (Keytruda; Merck) for the first-line treatment of adults with advanced renal-cell carcinoma (RCC). The FDA granted this combination a priority review and breakthrough therapy designation.
Read More
Tibsovo First Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma with IDH1 Mutation
FDA Approvals, News & Updates
October 2021, Vol 12, No 5
On August 25, 2021, the FDA approved ivosidenib (Tibsovo; Servier Pharmaceuticals), an oral IDH1 inhibitor, for the treatment of adults with previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) and an IDH1 mutation, as detected by an FDA-approved test. The FDA granted ivosidenib a priority review for this indication and an orphan drug designation.
Read More
Brukinsa Now Approved for Waldenström’s Macroglobulinemia
FDA Approvals, News & Updates
October 2021, Vol 12, No 5
On August 31, 2021, the FDA approved zanubrutinib (Brukinsa; BeiGene), a Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adults with Waldenström’s macroglobulinemia. Zanubrutinib was previously approved for the treatment of adults with mantle-cell lymphoma.
Read More
FDA Approves Rezurock for the Treatment of Chronic Graft-versus-Host Disease
FDA Approvals, News & Updates
October 2021, Vol 12, No 5
On July 16, 2021, the FDA approved belumosudil (Rezurock; Kadmon Holdings), a kinase inhibitor, for the treatment of patients aged ≥12 years with chronic graft-versus-host disease (GVHD) after failure of ≥2 previous lines of systemic therapy. The FDA granted belumosudil breakthrough therapy designation and priority review for this indication.
Read More
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma